...
首页> 外文期刊>Journal of Thoracic Disease >Remifentanil versus dexmedetomidine for treatment of cardiac surgery patients with moderate to severe noninvasive ventilation intolerance (REDNIVIN): a prospective, cohort study
【24h】

Remifentanil versus dexmedetomidine for treatment of cardiac surgery patients with moderate to severe noninvasive ventilation intolerance (REDNIVIN): a prospective, cohort study

机译:Remifentanil与Dexmedetomidine治疗心脏手术患者中度至严重的非侵入性通风不耐受(Rednivin):一项潜在的队列研究

获取原文

摘要

Background: The use of sedation to noninvasive ventilation (NIV) patients remains controversial, however, for intolerant patients who are uncooperative, administration of analgesics and sedatives may be beneficial before resorting to intubation. The aim of this study was to evaluate the efficacy of remifentanil (REM) versus dexmedetomidine (DEX) for treatment of cardiac surgery (CS) patients with moderate to severe NIV intolerance. Methods: This prospective cohort study of CS patients with moderate to severe NIV intolerance was conducted between January 2018 and March 2019. Patients were treated with either REM or DEX, decided by the bedside intensivist. Depending on the treatment regimen, the patients were allocated to one of two groups: the REM group or DEX group. Results: A total of 90 patients were enrolled in this study (52 in the REM group and 38 in the DEX group). The mitigation rate, defined as the percentage of patients who were relieved from the initial moderate to severe intolerant status, was greater in the REM group than DEX group at 15 min and 3 h (15 min: 83% vs. 61%, P=0.029; 3 h: 92% vs. 74%, P=0.016), although the mean mitigation rate (81% vs. 85%, P=0.800) was comparable between the two groups. NIV failure, defined as reintubation or death over the course of study, was comparable between the two groups (19.2% vs. 21.1%, respectively, P=0.831). There were no significant differences between the two groups in other clinical outcomes, including tracheostomy (15.4% vs. 15.8%, P=0.958), in-hospital mortality (11.5% vs. 10.5%, P=0.880), ICU length of stay (LOS) (7 vs. 7 days, P=0.802), and in-hospital LOS (17 vs. 19 days, P=0.589). Conclusions: REM was as effective as DEX in CS patients with moderate to severe NIV intolerance. Although the effect of REM was better than that of DEX over the first 3 h, the cumulative effect was similar between the two treatments.
机译:背景技术:使用镇静对非侵入性通气(NIV)患者仍然存在争议,然而,对于不合作的患者,镇痛药和镇静剂的施用可能是有益的,并且在诉诸插管之前可能是有益的。本研究的目的是评估雷芬丹内宁(REM)与右氧化吡吡啶(DEX)治疗心脏手术(CS)患者中度至严重核心不耐受的疗效的疗效。方法:2018年1月至2019年1月在2019年1月至3月期间对患有中度至严重核心不耐受的前瞻性队列研究。患者用REM或DEX治疗,由床头柜的强度决定。根据治疗方案,患者分配给两组中的一组:综合组或DEX组。结果:本研究共纳入90例患者(52例,在DEX组中的38组)。定义为从初始中度到严重的不宽容状态缓解的患者的减缓率,在15分钟和3小时(15分钟:83%vs.61%,P = 0.029; 3小时:92%与74%,P = 0.016),但两组之间平均缓解率(81%vs.85%,p = 0.800)。在研究过程中被定义为重新碰交或死亡,两组(分别为19.2%,分别为21.1%,P = 0.831)。两组在其他临床结果中没有显着差异,包括气管造口术(15.4%与15.8%,P = 0.958),住院死亡率(11.5%与10.5%,P = 0.880),ICU的住宿时间(LOS)(7 vs. 7天,P = 0.802)和医院LOS(17 vs.19天,P = 0.589)。结论:REM与中度至重度NIV不耐受的CS患者的DEX有效。虽然REM的效果优于DEX在前3小时的效果,但两种治疗之间的累积效果类似。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号